If it relates to Humanigen, I suppose we will see a PR about it.
If it doesn't legally relate to Humanigen, but we run out of funds, that could get sticky.
But I think the company has largely refocused on the use of lenz for covid, as it is likely more expeditious to generate revenue through the use of lenz in cocktails using the Janssen and Novavax vaccines.
Then, we can return our attention to the imperative of using lenz as a therapeutic to treat covid pneumonia.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.